E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
End stage renal disease patients undergoing a deceased donor kidney transplant |
|
E.1.1.1 | Medical condition in easily understood language |
End stage kidney disease patients undergoing a deceased donor kidney transplant |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10023438 |
E.1.2 | Term | Kidney transplant |
E.1.2 | System Organ Class | 100000004865 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Does Heme Arginate (HA) result in transplanted kidneys working quicker (reduction in delayed graft function) after transplantation compared with the placebo group. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives are: •To reduce the requirement for dialysis during the week post transplantation •To reduce the number of days to functioning graft •To determine if treatment influences renal function and acute rejection rates in the first 3 months •To determine whether treatment impacts on early post-transplant quality of life (first 3 months)
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Patients undergoing a kidney only transplant, or a dual kidney transplant, from a deceased donor will be invited to take part. • All participants will be at least 18 years old. There is no upper age limit. • All patients receiving standard immunosuppression for the individual centre will be included. • Meets the co-enrolment criteria outlined in section 4.4 of the protocol
|
|
E.4 | Principal exclusion criteria |
• Kidney transplant patients as part of a multi-organ transplant e.g. with pancreas or liver • Hepatitis C (HCV) +ve donor to HCV –ve recipient • Known hypersensitivity to heme arginate • Unable to give informed consent • Patients with porphyria, irrespective of whether they have ever received heme arginate or not, will be excluded. • Previous randomisation into this study (or HOT study) • Women who are pregnant or lactating • Kidneys that have undergone ex-vivo normothermic perfusion (EVNP) • Patients with known liver disease, epilepsy, brain injury or disease. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Delayed Graft Function (DGF) - defined as a failure of a spontaneous fall in creatinine of >10% for each 3 consecutive day period in the first week following transplantation, or equivalent. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Daily for the first seven days post transplant or until discharge from hospital if before day 7 post-op. |
|
E.5.2 | Secondary end point(s) |
i. Requirement for dialysis during the week post transplantation ii. Number of days to functioning graft (defined as a spontaneous fall in creatinine of ≥10% over a period of 3 consecutive days in the first 7 days post-transplant, or equivalent). iii. Length of stay on index admission for transplant iv. Serum creatinine at 1 and 3 months’ post-transplant v. Biopsy-proven acute rejection during first 3 months vi. SF-36 quality of life questionnaire at days 0 (pre-transplant), 7 and approximately three months post-transplant vii. Cost-effectiveness (Cost per QALY gained)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
i. Daily for the first seven days post transplant or until discharge from hospital if before day 7 post-op. ii. Daily for the first seven days post transplant or until discharge from hospital if before day 7 post-op. iii. Confirmed at day 30 post-op if discharge is not within the first 7 days post transplant. iv. Assessed/confirmed at follow up appointment on day 90 post-op v. Completed at Day 0, 7 and 90 post transplant vi. Assessed as part of trial analysis using data collected throughout the course of the patient participation in the trial. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 12 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 12 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of study is defined as the point at which the trial database is locked following resolution of all data queries by the trial management team and statisticians.
This definition allows for long term follow up data to be obtained and incorporated into final report within the regulator and sponsor timelines. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 30 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 2 |